IMPROVE 2025: The 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM

Clinical Obesity Pub Date : 2026-09-10 DOI:10.1111/cob.70109

Jesús Argente, Erica L. T. van den Akker, Metin Cetiner, Karine Clément, Elizabeth Forsythe, Alastair Garfield, Peter Kühnen, Gabriel Ángel Martos-Moreno, David Meeker, Hermann L. Müller, Hanneke M. van Santen, Julia von Schnurbein, Bérénice Segrestin, Tomohiro Tanaka, Manuel Tena-Sempere, Martin Wabitsch, Stefanie Zorn, I. Sadaf Farooqi

{"title":"IMPROVE 2025: The 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence","authors":"Jesús Argente, Erica L. T. van den Akker, Metin Cetiner, Karine Clément, Elizabeth Forsythe, Alastair Garfield, Peter Kühnen, Gabriel Ángel Martos-Moreno, David Meeker, Hermann L. Müller, Hanneke M. van Santen, Julia von Schnurbein, Bérénice Segrestin, Tomohiro Tanaka, Manuel Tena-Sempere, Martin Wabitsch, Stefanie Zorn, I. Sadaf Farooqi","doi":"10.1111/cob.70109","DOIUrl":null,"url":null,"abstract":"<p>An international cohort of 161 clinicians and researchers from 19 countries attended the 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) in Prague, Czech Republic, on 2–4 July 2025. The aims of the meeting were to advance understanding of hyperphagia and obesity caused by defects in the melanocortin-4 receptor (MC4R) pathway and to support peer-to-peer sharing of clinical experience and emerging evidence. The programme comprised four sessions covering hyperphagia, monogenic MC4R pathway diseases, Bardet–Biedl syndrome and acquired hypothalamic obesity. Discussions focused on defining and measuring hyperphagia, updates in genetic diagnostics and natural history, real-world and trial data on targeted therapies and practical multidisciplinary models of care with earlier intervention. Patient and caregiver quality of life remained central throughout. These Proceedings summarise the key updates, discussions and initiatives generated at IMPROVE 2025.</p>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"16 5","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cob.70109","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Obesity","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cob.70109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

An international cohort of 161 clinicians and researchers from 19 countries attended the 3rd International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) in Prague, Czech Republic, on 2–4 July 2025. The aims of the meeting were to advance understanding of hyperphagia and obesity caused by defects in the melanocortin-4 receptor (MC4R) pathway and to support peer-to-peer sharing of clinical experience and emerging evidence. The programme comprised four sessions covering hyperphagia, monogenic MC4R pathway diseases, Bardet–Biedl syndrome and acquired hypothalamic obesity. Discussions focused on defining and measuring hyperphagia, updates in genetic diagnostics and natural history, real-world and trial data on targeted therapies and practical multidisciplinary models of care with earlier intervention. Patient and caregiver quality of life remained central throughout. These Proceedings summarise the key updates, discussions and initiatives generated at IMPROVE 2025.

查看原文本刊更多论文

改善2025：第三届通路相关肥胖国际会议：愿景和证据。

来自19个国家的161名临床医生和研究人员参加了2025年7月2日至4日在捷克共和国布拉格举行的第三届通路相关肥胖：视觉与证据国际会议（IMPROVE）。会议的目的是促进对黑素皮质素-4受体（MC4R）通路缺陷引起的贪食和肥胖的理解，并支持临床经验和新证据的点对点共享。该方案包括四个环节，涉及贪食、单基因MC4R通路疾病、Bardet-Biedl综合征和获得性下丘脑肥胖。讨论的重点是贪食症的定义和测量、基因诊断和自然病史的最新进展、靶向治疗的真实世界和试验数据以及早期干预的实用多学科护理模式。患者和护理者的生活质量始终是中心问题。这些会议记录总结了改善2025的主要更新、讨论和倡议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Obesity ENDOCRINOLOGY & METABOLISM-

CiteScore

5.90

自引率

3.00%

发文量

期刊介绍： Clinical Obesity is an international peer-reviewed journal publishing high quality translational and clinical research papers and reviews focussing on obesity and its co-morbidities. Key areas of interest are: • Patient assessment, classification, diagnosis and prognosis • Drug treatments, clinical trials and supporting research • Bariatric surgery and follow-up issues • Surgical approaches to remove body fat • Pharmacological, dietary and behavioural approaches for weight loss • Clinical physiology • Clinically relevant epidemiology • Psychological aspects of obesity • Co-morbidities • Nursing and care of patients with obesity.